Skip header and navigation

Narrow By

   MORE

7 records – page 1 of 1.

5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Notes
Previous title: 5-Aminosalicylate (5-ASA)
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1483
Less detail

Adalimumab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1207
Available Online
View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Adalimumab (Humira) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1207
Less detail

Corticosteroid therapy in inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1546
Available Online
View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Corticosteroid therapy in IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Prednisone
Subjects (LCSH)
Inflammatory bowel diseases
Prednisone
Specialty
Gastrointestinal System
Medications
Abstract
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Notes
This pamphlet replaced pamphlet 1139, Prednisone Therapy.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1546
Less detail

Golimumab (Simponi®) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1641
Available Online
View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Golimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Golimumab (Simponi) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1641
Less detail

Inflammatory Bowel Disease and Familial Adenomatous Polyposis : Clinical Management and Patients' Quality of Life

https://libcat.nshealth.ca/en/permalink/provcat29444
edited by Gian Gaetano Delaini. --Milan: Springer-Verlag Italia , c2006.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Delaini, Gian Gaetano
Responsibility
edited by Gian Gaetano Delaini
Place of Publication
Milan
Publisher
Springer-Verlag Italia
Date of Publication
c2006
ISBN
9788847004344
Subjects (MeSH)
Adenomatous Polyposis Coli - therapy
Inflammatory Bowel Diseases - complications
Inflammatory Bowel Diseases - diagnosis
Inflammatory Bowel Diseases - therapy
Subjects (LCSH)
Colorectal diseases
Format
e-Book
Location
Online
Less detail

Infliximab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1140
Available Online
View Pamphlet
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Subjects (LCSH)
Inflammatory bowel diseases
Infliximab
Abstract
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Infliximab (Remicade) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1140
Less detail

Treatment of Inflammatory Bowel Disease with Biologics

https://libcat.nshealth.ca/en/permalink/provcat42935
edited by Adam S. Cheifetz, Joseph D. Feuerstein. --Cham, Switzerland: Springer , c2018.
Available Online
View e-Book
Location
Online
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment …
Available Online
View e-Book
Other Authors
Cheifetz, Adam S.
Feuerstein, Joseph D.
Responsibility
edited by Adam S. Cheifetz, Joseph D. Feuerstein
Place of Publication
Cham, Switzerland
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xi, 335 p.) : 22 illus., 19 illus. in color
ISBN
9783319602769
9783319602752 (print ed.)
9783319602776 (print ed.)
9783319868233 (print ed.)
Subjects (MeSH)
Anti-Inflammatory Agents - therapeutic use
Biological Products - therapeutic use
Inflammatory Bowel Diseases - drug therapy
Specialty
Biological Therapy
Gastroenterology
Abstract
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
Contents
Mechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics—Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies.
Format
e-Book
Location
Online
Less detail

7 records – page 1 of 1.